Gilles Alberici

Gilles Alberici is a prominent figure in the pharmaceutical industry with over 35 years of experience, particularly in the development of drugs for rare diseases. He currently serves as the Executive Chairman of ORPHELIA Pharma, a French company specializing in pediatric medicines.13

Career Highlights

• Founder and President of initiative OCTALFA, a family-owned organization that invests in life sciences companies12
• Founder of OPi, Pharmaceuticals for Rare Diseases2
• Chairman of the Board at ORPHELIA Pharma (appointed in 2015)13
• Involved with OREGA Biotech

Experience and Expertise

Gilles Alberici has a deep understanding of pharmacology and drug development for rare diseases. He has been instrumental in taking more than ten products through clinical trials.2 His expertise spans various areas of the pharmaceutical and biotechnology sectors, including:

• Drug formulation development for pediatric indications
• Neurology and metabolic diseases
• Immuno-oncology

Education and Early Career

Alberici studied at Université Paris Sud (Paris XI) and has worked with organizations such as Gustave Roussy, Institut Mérieux, and IMTIX.

Current Roles

• Executive Chairman at ORPHELIA Pharma13
• President of OCTALFA2
• President of Fonds de Dotation Dominique & Tom Alberici

Achievements at ORPHELIA Pharma

Under Alberici's leadership, ORPHELIA Pharma has made significant strides in developing pediatric formulations of existing drugs. The company has been working on several projects, particularly in the field of epilepsy, and has been utilizing European regulations on pediatric medicines to bring new treatments to market.1

Gilles Alberici's extensive experience and leadership have been crucial in driving ORPHELIA Pharma's mission to develop and commercialize innovative pediatric medicines, addressing unmet needs in areas such as neurology and rare diseases.